US health plans routinely restrict coverage of high-cost specialty drugs by using clinical criteria or step therapy. This study explored concerns that drug prices and rebates unduly influence the frequency of these restrictions.
US health plans routinely restrict coverage of high-cost specialty drugs by using clinical criteria or step therapy. This study explored concerns that drug prices and rebates unduly influence the frequency of these restrictions.